RecruitingNot ApplicableNCT04133077

Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer

A Prospective Study of Xenografts Development From Samples Taken From Surgical Specimens of Patients With Triple Negative or Luminal B Breast Cancer

Sponsor

Centre Jean Perrin

Enrollment

85 participants

Start Date

Nov 19, 2021

Study Type

INTERVENTIONAL

Conditions

Breast Cancer Female

Summary

Patient derived xenografts (PDX) from mammary tumors are usually made from metastatic tumors. Indeed, PDX from primitive mammary tumors or after neoadjuvant treatment are still rare. However, the realization of such PDX (from primitive mammary tumors or after neoadjuvant treatment) would make it possible to have a better knowledge of the tumor heterogeneity to the therapeutic response, to explore the models of tumor evolution during metastatic progression and also observe the mechanisms of tumor resistance in the case of non-metastatic tumors. It therefore seems necessary to develop PDX from primitive tumors in order to observe firstly the success rate of PDX; on the other hand, the drift of the initial heterogeneity, measured by comparison of the histomolecular profile of the tumors with that of the PDXs. It aims to develop xenografts from tumor samples from surgical specimens of patients with triple negative or luminal B breast cancer.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is developing laboratory models (called patient-derived xenografts) from tumor tissue removed during surgery. These models help researchers test new cancer treatments in the lab. It is for women with specific types of breast cancer who are having surgery. **You may be eligible if...** - You are an adult woman - You have triple-negative breast cancer (a type that lacks estrogen, progesterone, and HER2 receptors), metaplastic triple-negative breast cancer, inflammatory triple-negative breast cancer, or Luminal B breast cancer - You are receiving neoadjuvant chemotherapy (before surgery) or having primary surgery - After treatment, there is remaining tumor tissue of a sufficient size for the study - You have good overall health (ECOG performance status ≤ 2) **You may NOT be eligible if...** - You are pregnant - You are deprived of liberty by court or administrative decision - You received neoadjuvant radiotherapy or hormone therapy instead of chemotherapy - You refuse to participate Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.